• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma.

作者信息

Mishra Kundan, Jandial Aditya, Sandal Rajeev, Lad Deepesh, Prakash Gaurav, Khadwal Alka, Malhotra Pankaj

机构信息

Department of Internal Medicine, Post-Graduate Institute of Medical Education and Research, Chandigarh, 160012 India.

出版信息

Indian J Hematol Blood Transfus. 2019 Jul;35(3):584-586. doi: 10.1007/s12288-019-01135-4. Epub 2019 May 10.

DOI:10.1007/s12288-019-01135-4
PMID:31388282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6646455/
Abstract
摘要

相似文献

1
Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma.新诊断多发性骨髓瘤患者接受基于达雷妥尤单抗的联合化疗后动员不佳
Indian J Hematol Blood Transfus. 2019 Jul;35(3):584-586. doi: 10.1007/s12288-019-01135-4. Epub 2019 May 10.
2
Daratumumab in untreated newly diagnosed multiple myeloma.达雷妥尤单抗用于未经治疗的新诊断多发性骨髓瘤
Ther Adv Hematol. 2019 Dec 23;10:2040620719894871. doi: 10.1177/2040620719894871. eCollection 2019.
3
Daratumumab for the treatment of multiple myeloma.达雷妥尤单抗用于治疗多发性骨髓瘤。
Expert Opin Biol Ther. 2017 Jul;17(7):887-893. doi: 10.1080/14712598.2017.1322578. Epub 2017 May 2.
4
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗未经治疗的多发性骨髓瘤。
N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.
5
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗新诊断多发性骨髓瘤（ALCYONE）的总生存：一项随机、开放标签、3 期临床试验。
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
6
Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis.达雷妥尤单抗联合标准治疗方案用于初诊多发性骨髓瘤患者：一项网状 Meta 分析。
Eur J Haematol. 2019 Dec;103(6):542-551. doi: 10.1111/ejh.13317. Epub 2019 Oct 1.
7
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.针对来那度胺和硼替佐米耐药的多发性骨髓瘤患者，CD38 靶向免疫化疗的治疗潜力的临床前证据。
Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14.
8
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.FDA 批准概要：达雷妥尤单抗治疗既往接受过一种治疗的多发性骨髓瘤。
Oncologist. 2017 Nov;22(11):1347-1353. doi: 10.1634/theoncologist.2017-0229. Epub 2017 Sep 13.
9
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.与人类抗KIR抗体IPH2102和来那度胺联合使用时，达雷妥尤单抗介导的原发性多发性骨髓瘤细胞裂解作用增强。
Haematologica. 2015 Feb;100(2):263-8. doi: 10.3324/haematol.2014.117531. Epub 2014 Dec 15.
10
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.达雷妥尤单抗、埃罗妥珠单抗与多发性骨髓瘤治疗性单克隆抗体的研发
Clin Pharmacol Ther. 2017 Jan;101(1):81-88. doi: 10.1002/cpt.550.

引用本文的文献

1
Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study.透析依赖与多发性骨髓瘤的不良预后相关：一项多中心回顾性队列研究。
Ther Adv Med Oncol. 2025 Aug 21;17:17588359251357682. doi: 10.1177/17588359251357682. eCollection 2025.
2
Moving Beyond G-CSF Mobilization-Learning From a 15-Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma.超越粒细胞集落刺激因子动员——从多发性骨髓瘤不同干细胞动员方案的15年经验中学习
Cancer Med. 2025 Jul;14(14):e71068. doi: 10.1002/cam4.71068.
3
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review.抗CD38单克隆抗体疗法对多发性骨髓瘤患者CD34+造血干细胞动员、采集及植入的影响——一项系统评价
Pharmaceuticals (Basel). 2024 Jul 15;17(7):944. doi: 10.3390/ph17070944.
4
Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments.多发性骨髓瘤中的干细胞动员：挑战、策略和最新进展。
Ann Hematol. 2023 May;102(5):995-1009. doi: 10.1007/s00277-023-05170-0. Epub 2023 Mar 22.
5
Peri-transplant Stem Cell Kinetics After Daratumumab-Based Induction in Patients with Multiple Myeloma: Response to Mishra et al.达雷妥尤单抗诱导治疗的多发性骨髓瘤患者移植后干细胞动力学：对米什拉等人研究的回应
Indian J Hematol Blood Transfus. 2020 Oct;36(4):763-765. doi: 10.1007/s12288-020-01273-0. Epub 2020 Mar 17.

本文引用的文献

1
Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma.“通用型”泊马度胺治疗复发难治性多发性骨髓瘤的真实世界经验。
Leuk Lymphoma. 2019 Apr;60(4):1102-1104. doi: 10.1080/10428194.2018.1508675. Epub 2018 Oct 15.
2
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗未经治疗的多发性骨髓瘤。
N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.
3
Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?多发性骨髓瘤中的外周血干细胞动员：生长因子还是化疗？
World J Transplant. 2017 Oct 24;7(5):250-259. doi: 10.5500/wjt.v7.i5.250.
4
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.优化自体干细胞动员策略以改善患者结局：共识指南和建议。
Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17.
5
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.普乐沙福与粒细胞集落刺激因子对比安慰剂与粒细胞集落刺激因子用于动员多发性骨髓瘤患者造血干细胞以进行自体干细胞移植
Blood. 2009 Jun 4;113(23):5720-6. doi: 10.1182/blood-2008-08-174946. Epub 2009 Apr 10.